AMG 386 + motesanib

**AMG 386 + motesanib** is an experimental combination therapy consisting of two investigational agents, each targeting tumor angiogenesis by distinct but complementary mechanisms. - **AMG 386** (also known as 2xCon4) is a first-in-class peptibody (peptide-Fc fusion protein) that inhibits angiogenesis by selectively binding to and blocking both angiopoietin-1 (Ang1) and angiopoietin-2 (Ang2), thereby preventing their interaction with the Tie2 receptor, which mediates vascular stabilization and remodeling[1][2][3][5]. This dual Ang1/2 neutralization leads to inhibition of postnatal angiogenesis essential for tumor growth. - **Motesanib** is a small molecule, orally administered antagonist of vascular endothelial growth factor (VEGF) receptors 1, 2, and 3, as well as platelet-derived growth factor (PDGF) receptor and stem cell factor (SCF) receptor[1]. Its mechanism involves the inhibition of angiogenesis and lymphangiogenesis, key processes in tumor vascularization and growth. Clinical trials have shown both compounds to have antitumor activity in combination with chemotherapy, and combination of angiopoietin/Tie2 and VEGF pathway inhibition is under investigation for additive or synergistic effects in solid tumors.

Other names

AMG 386 + motesanib